Abstracts tagged "interferons"

Abstract Number: 3220 • 2016 ACR/ARHP Annual Meeting
Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis
Theresa L. Wampler Muskardin¹, Wei Fan², Zhongbo Jin³, Mark A. Jensen⁴, Jessica M. Dorschner³, Yogita Ghodke-Puranik³, Kerry Wright¹, John M. Davis III⁵, Eric L. Matteson¹, Clement Michet Jr.¹, Thomas G. Mason II⁶, Scott T. Persellin⁷, Daniel Schaffer¹, Betty Dicke¹, Danielle Vsetecka³ and Timothy B. Niewold⁸, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, ⁷Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: In rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy, and remission is…
Abstract Number: 761 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
L Santiago¹, B Wang², P Brohawn², L Wang², G Illei² and L Roskos², ¹MedImmune, Mountain View, CA, ²MedImmune, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon–α receptor (IFNAR1) currently in development for the…
Abstract Number: 774 • 2016 ACR/ARHP Annual Meeting
BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers
David Martin, Lauren Stevenson, Pratapa Prasad, Karen Smirnakis, Amy Kao, Dania Rabah, Wenting Wang and Nathalie Franchimont, Biogen, Cambridge, MA
Background/Purpose: Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). In SLE, immune complexes stimulate plasmacytoid dendritic cells (pDCs) to…
Abstract Number: 792 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
R Furie¹, L Wang², J Drappa² and G Illei², ¹Northwell Health, Great Neck, NY, ²MedImmune, Gaithersburg, MD
Background/Purpose: Post-hoc analysis of two Phase III studies of belimumab1 showed that an SRI(4) response is associated with clinically meaningful benefits, irrespective of treatment assignment.…
Abstract Number: 864 • 2016 ACR/ARHP Annual Meeting
Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses
Shoichi Fukui¹, Naoki Iwamoto², Toshimasa Shimizu², Masataka Umeda², Ayako Nishino³, Yoshiro Horai², Tomohiro Koga⁴, Shin-ya Kawashiri⁵, Kunihiro Ichinose¹, Yasuko Hirai², Mami Tamai¹, Hideki Nakamura⁵, Tomoki Origuchi⁶, Kiyoshi Migita⁷, Yukitaka Ueki⁸ and Atsushi Kawakami⁹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, ⁴Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis (TAK) include age at disease onset ≤ 40 years. We aimed…
Abstract Number: 1518 • 2016 ACR/ARHP Annual Meeting
Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
JoAnn Ball¹, Kelsy Greenwald¹, Atul A. Deodhar² and Kevin L. Winthrop³, ¹Rheumatology, Desert Medical Advances, Palm Desert, CA, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Oregon Health and Sciences University, Portland, OR
Background/Purpose: Citrullinated BiP is a newly described target for cyclic citrullinated peptide(CCP). BiP in both serum and synovial fluid is over-expressed in RA patients and…
Abstract Number: 1831 • 2016 ACR/ARHP Annual Meeting
A Novel Graph Theoretic Approach Applied to Modular Repertoire Analysis Identifies a Dual Molecular Progression in Adult SLE Patients, with Distinct Interferon and Neutrophil Transcription Patterns
Ilya Korsunski¹, Noémie Jourde-Chiche^2,3, Peter K. Gregersen¹, Damien Chaussabel⁴, Laurent Chiche⁵ and Naomi I Maria⁶, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ³Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, ⁴Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, ⁵internal medicine, Hopital Europeen, Marseille, France, ⁶Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Gene expression studies support a pivotal role for type I interferon (IFN) in SLE. Previous work using a modular repertoire analysis based on co-clustered…
Abstract Number: 1832 • 2016 ACR/ARHP Annual Meeting
Increased Interferon b Expression in Bone Marrow Mediates a Senescent Phenotype and Impaired Production of Immunomodulatory Factors By SLE Mesenchymal Stromal Cells
Lin Gao¹, Jennifer H. Anolik² and R. John Looney², ¹medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow mesenchymal stromal cells (MSCs) are multipotent stem cells that create a special microenvironment for hematopoiesis and immunity. MSCs display robust immunomodulatory properties…
Abstract Number: 2009 • 2016 ACR/ARHP Annual Meeting
The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures
JT Merrill¹, R Furie², Victoria P. Werth^3,4, M Khamashta⁵, J Drappa⁶, L Wang⁶ and G Illei⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Northwell Health, Great Neck, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia V.A. Medical Center, Philidelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, London, United Kingdom, ⁶MedImmune, Gaithersburg, MD
Background/Purpose: The Phase IIb MUSE study (NCT01438489) of intravenous anifrolumab in 305 patients with moderate to severely active SLE (300 or 1,000 mg vs. placebo,…
Abstract Number: 2057 • 2016 ACR/ARHP Annual Meeting
TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling
Sonya Wolf¹, Tamra J. Reed², Chaim O. Jacob³ and J. Michelle Kahlenberg⁴, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Medicine/Div of Rheumatology, USC School of Medicine, Los Angeles, CA, ⁴Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies, immune complex deposition, elevated production of type I interferons (IFNs),…
Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Ruth D.E. Fritsch-Stork², Marjan A. Versnel³, Ronald H.W.M. Derksen⁴, Joel A.G. van Roon^5,6 and Timothy R.D.J. Radstake^5,6, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
Abstract Number: 2471 • 2015 ACR/ARHP Annual Meeting
Increased Muscle Interferon-Gamma Expression Levels in Juvenile Dermatomyositis
Gian Marco Moneta¹, Adele D'Amico², Margherita Verardo³, Denise Pires Marafon⁴, Luisa Bracci Laudiero⁵, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Department Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy, ²Department of Neuroscience,, Unit of Neuromuscular and Neurodegenrative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy, ³Department of Neuroscience, Unit of Neuromuscular and Neurodegenrative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy, ⁴Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵Rheumatology Laboratory, Bambino Gesú Children Hospital, Rome, Italy, ⁶Pediatric Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁷Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
Background/Purpose : Juvenile dermatomyositis (JDM) is a rare autoimmune disorder characterized by muscle weakness, skin rashes and other systemic features. The immunopathogenesis of JDM is…
Abstract Number: 721 • 2015 ACR/ARHP Annual Meeting
Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, M Khamashta², L Wang³, J Drappa³, W Greth³ and G Illei³, ¹Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³MedImmune, Gaithersburg, MD
Background/Purpose: Most randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors to ensure a balanced allocation of subgroups that might respond differently…
Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting
Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Yuli McCann¹, Meredith Barnes¹ and Grant Hughes², ¹Medicine, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Female sex steroids are important modulators of autoimmunity. Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…
Abstract Number: 801 • 2015 ACR/ARHP Annual Meeting
Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1
Xuebing Feng¹, Weiwei Chen², Lihui Xiao¹ and Lingyun Sun², ¹Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: While type I interferon (IFN) has been linked to atherosclerosis progression in systemic lupus erythematosus (SLE), little is known about its regulation and intervention.…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].